Anticancer Vaccines

被引：24

作者：

Bergman, Philip J. ^{[1
,2
]}

机构：

[1] Brightheart Vet Ctr, Armonk, NY 10504 USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE | 2007年 / 37卷 / 06期

关键词：

D O I：

10.1016/j.cvsm.2007.06.005

中图分类号：

S85 [动物医学（兽医学）];

学科分类号：

0906 ;

摘要：

With the tools of molecular biology and a greater understanding of mechanisms to harness the immune system, effective tumor immunotherapy is becoming a reality. This new class of therapeutics offers a more targeted, and therefore precise, approach to the treatment of cancer. The recent conditional licensure of a xenogeneic DNA vaccine for advanced canine malignant melanoma strongly suggests that immunotherapy can play an extremely important role alongside the classic cancer treatment triad components of surgery, radiation therapy, and chemotherapy.

引用

页码：1111 / +

页数：11

共 58 条

[1] Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model [J].

Akhtar, N ;

Padilla, ML ;

Dickerson, EB ;

Steinberg, H ;

Breen, M ;

Auerbach, R ;

Helfand, SC .

NEOPLASIA, 2004, 6 (02) :106-116

[2] Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma [J].

Alexander, AN ;

Huelsmeyer, MK ;

Mitzey, A ;

Dubielzig, RR ;

Kurzman, ID ;

MacEwen, EG ;

Vail, DM .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (04) :433-442

[3] Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center [J].

Bergman, PJ ;

Camps-Palau, MA ;

McKnight, JA ;

Leibman, NF ;

Craft, DM ;

Leung, C ;

Liao, J ;

Riviere, I ;

Sadelain, M ;

Hohenhaus, AE ;

Gregor, P ;

Houghton, AN ;

Perales, MA ;

Wolchok, JD .

VACCINE, 2006, 24 (21) :4582-4585

[4]

Bergman PJ, 2003, CLIN CANCER RES, V9, P1284

[5]

BERGMAN PJ, 2002, VET ONCOLOGY SECRETS, P79

[6] Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer [J].

Biller, B. J. ;

Elmslie, R. E. ;

Burnett, R. C. ;

Avery, A. C. ;

Dow, S. W. .

VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2007, 116 (1-2) :69-78

[7] INTRAVENOUS BCG THERAPY OF MAMMARY-CARCINOMA IN BITCHES AFTER SURGICAL EXCISION OF PRIMARY TUMOR [J].

BOSTOCK, DE ;

GORMAN, NT .

EUROPEAN JOURNAL OF CANCER, 1978, 14 (08) :879-883

[8] Immunosuppressive cytokines in the regional lymph node of a dog suffering from oral malignant melanoma [J].

Catchpole, B ;

Gould, SM ;

Kellett-Gregory, LM ;

Dobson, JM .

JOURNAL OF SMALL ANIMAL PRACTICE, 2002, 43 (10) :464-467

[9] Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases [J].

Dow, S ;

Elmslie, R ;

Kurzman, I ;

MacEwen, G ;

Pericle, F ;

Liggitt, D .

HUMAN GENE THERAPY, 2005, 16 (08) :937-946

[10] In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma [J].

Dow, SW ;

Elmslie, RE ;

Willson, AP ;

Roche, L ;

Gorman, C ;

Potter, TA .

JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (11) :2406-2414

← 1 2 3 4 5 6 →